Abstract 488P
Background
Clinical investigations have great interest in understanding how ground-glass opacities (GGO) evolve into solid nodular lung adenocarcinoma (LUAD). However, there exists a dearth of research on ecosystem-level dynamics. Comprehensive insights into this phenomenon hinge on patient biopsies, which, when coupled with advanced single cell studies, hold the potential to unravel the intricacies of GGO progression and its transition into solid nodular LUAD.
Methods
We implemented a machine-learning framework to analyze scRNA-seq and WGS data derived from 55 patients stratified based on radiological patterns. In combination with in situ multiplex IF and HLA-immunopeptidome, we analysed the immune-ecosystem associated neoantigen presentation, followed by validation with HLA-tetramer CD8 T cell assay. Based on these methods, we consequently refined early-stage LUAD classification.
Results
We defined six lung immune multicellular ecotypes (LIMEs), in which two cancer cell state-associated LIMEs were implicated in distinct radiological patterns. These early stage malignant cells, through presenting GGO-associated neoantigens, were recognized by CXCL13+ CD8 T cells that formed an anti-tumoral LIME with other stromal cells. Solid nodular specific LIMEs, containing CTHRC1+ CAFs, SPP1+ TAMs and BANK1+ B cells, through inter-ecotype interactions, drove CD8 T cell exhaustion, leading to tumour progression.
Conclusions
This work offers an ecosystem-level portrayal of early-stage LUAD. It furnishes a resource for delving into the pre-malignant transformation of lung epithelium and its associated microenvironment. It outlines both intrinsic and extrinsic mechanisms that underpin the emergence of GGO and subsolid patterns. It imparts biological rationales as to select patients with early-stage LUAD might benefit from perioperative adjuvant therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
West China Hospital, Sichuan University, Chengdu, China.
Funding
National Science Fondation of China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract